Meeting
2021 ASCO Annual Meeting
Comparison of dose modification strategies to address expected hematologic toxicities in treatment-naïve higher-risk (HR) MDS patients treated with venetoclax + azacitidine.
Authors
Jacqueline Suen Garcia
Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
Jacqueline Suen Garcia , Andrew Wei , Uma Borate , Chun Yew Fong , Maria R. Baer , Daniel Nowak , Pierre Peterlin , Joseph G. Jurcic , Meagan Jacoby , Uwe Platzbecker , Olatoyosi Odenike , Ilona Cunningham , Ying Zhou , David Hoffman , Kiran Naqvi , Steve Kye , Guillermo Garcia-Manero
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies
Sub Track
Myelodysplastic Syndromes (MDS)
Clinical Trial Registration Number
NCT02942290
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 7041)
DOI
10.1200/JCO.2021.39.15_suppl.7041
Abstract #
7041
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated myeloid malignancies.
First Author: Curtis Andrew Lachowiez
Poster
2020 ASCO Virtual Scientific Program
Phase II study of lower-dose pracinostat plus azacitidine safety and efficacy in patients with high/very high-risk myelodysplastic syndromes.
First Author: Ehab L. Atallah
Poster
2018 ASCO Annual Meeting
Phase 1b study of venetoclax in combination with azacitidine in patients with treatment-naïve higher-risk myelodysplastic syndromes.
First Author: Chun Yew Fong
Poster
2023 ASCO Annual Meeting
Iadademstat in combination with gilteritinib for patients with mutated FLT3 relapsed/refractory acute myeloid leukemia.
First Author: Amir Tahmasb Fathi